Assistant Professor
Academic disciplines: 
U08, Piano: P02, Stanza: 2040
Via Cadore 48 - 20900 MONZA


He is leading translational research aimed to improve patient care by accelerating the development and delivery of personalised healthcare, including personalised therapies and diagnostics, applied to neurodegenerative, neuroimmunological and cerebrovascular disorders, particularly on the immune-mediated mechanisms and the amyloid-related imaging abnormalities (ARIA) in the pathogenesis of both rare diseases, i.e. Cerebral Amyloid Angiopathy-related inflammation (CAA-ri), and during immunotherapy trials of Alzheimer’s disease. 
He has more than 10 years experience in the discovery and validation of diagnostic, prognostic and therapeutic biomarkers and tools.
Dr Piazza is the founding Member and Coordinator of the inflammatory Cerebral Amyloid Angiopathy and Alzheimer’s disease βiomarkers International Network (iCAβ), a World-Wide Consortium involving 35 leading Centers of Excellence on AD and CAA from 12 different Countries, established in 2012
The validation of biomarkers of ARIA, as well as the definition of clinico-therapeutic recommendations to guide CAA and AD immunotherapy trials, is the main goal of the the biomarkARIA Research Project (P.I. Dr. Piazza) and iCAB International Network , the largest worldwide effort aimed at deciphering the pathogenetic mechanisms of CAA-ri and ARIA in a translational and cooperatively-open design between Academia and pharma companies.

FB page Link: https://www.facebook.com/icabinternational
WebSite: https://sites.google.com/site/icabinternationalnetwork/


  • Piazza, F., & Bengt, W. (2016). Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?. JOURNAL OF ALZHEIMER'S DISEASE, 52(2), 417-420. Detail
  • Auriel, E., Charidimou, A., Gurol, M., Ni, J., Van Etten, E., Martinez-Ramirez, S., et al. (2016). Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA NEUROLOGY, 73(2), 197-202. Detail
  • Difrancesco, J.C., Longoni, M., & Piazza, F. (2015). Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. FRONTIERS IN NEUROLOGY, 6. Detail
  • Piazza, F., Greenberg, S.M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., et al. (2013). Anti-Aβ autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies. ANNALS OF NEUROLOGY, 73(4), 449-458. Detail
  • Piazza, F., Galimberti, G., Conti, E., Isella, V., Perlangeli, M.V., Speranza, T., et al. (2012). Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. NEUROBIOLOGY OF AGING, 33(2), 226-233. Detail